计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
避光,-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
PR5-LL-CM01 is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor ( IC 50 = 7.5 μM). Anti-tumor activies.
In Vitro
PR5-LL-CM01 has a range of IC 50 at 2-4 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1, and a range of IC 50 at 10-11 μM in CRC cells (HT29, HCT116 and DLD1). PR5-LL-CM01 has higher efficacy to specifically inhibit cancer cells and demonstrated low toxicity in normal cells. PR5-LL-CM01 strongly inhibited colony forming ability in both PANC1 and HT29 cells. PR5-LL-CM01 inhibits NF-κB activation and its target gene expression in PDAC and CRC cells. PR5-LL-CM01 (0-15 μM) dramatically decreases TNFα and IL8 expression in both PANC1 and HT29 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PR5-LL-CM01 (20mg/kg; i.p.; 3 times per week) displays significant anti-tumor effect . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks old Male NSG mice (bearing PANC1 or HT29 cells) Dosage: 20 mg/kg (drug stock dissolved in 1:1 Cremophor:ethanol solution) Administration: Intraperitoneally 3 times per week; 32 days (PANC1 model); 10 days (HT29 model) Result: Led to significant tumor inhibition in both PANC1 and HT29 xenografted mice. Did not visibly affect the mice body weight.
Form:Solid